CTGov Compliance My Organizations

Compliance Rate

Compliance Rate 0%

Compliant submissions 0

Incompliant submissions 0

Total trials 0

My Organizations' Clinical Trials

Showing 225 of 308 entries

View as:

Plerixafor Plus Granulocyte Colony-stimulating Factor (G-CSF) For Mobilization And Collection Of Peripheral Hematopoietic Stem Cells In Japanese Participants With Multiple Myeloma

Phase: N/A Priority: Normal

NCT ID: NCT02221479 Org: User:

Start: 10/31/14 End: 07/31/15 Due: 07/31/16

Fabry Disease Registry & Pregnancy Sub-registry

Phase: N/A Priority: Normal

NCT ID: NCT00196742 Org: User:

Start: 07/31/01 End: 01/31/34 Due: 01/31/35

LEMTRADA Pregnancy Registry in Multiple Sclerosis

Phase: N/A Priority: Normal

NCT ID: NCT03774914 Org: User:

Start: 09/01/15 End: 11/22/21 Due: 11/22/22

Treatment With AMD3100 (Plerixafor) in MM Patients to Mobilize PBCs For Collection and for Transplantation

Phase: N/A Priority: Normal

NCT ID: NCT00396383 Org: User:

Start: 11/30/04 End: 05/31/07 Due: 05/31/08

A Screening Study Evaluating Disease Status of Gaucher Type I Patients

Phase: N/A Priority: Normal

NCT ID: NCT00795197 Org: User:

Start: 12/31/08 End: 12/31/09 Due: 12/31/10

Evaluation of Approved Weight-Based Dose Compared to Fixed Dose of Plerixafor in Patients With Non-Hodgkin's Lymphoma (NHL) Weighing Less Than 70 Kilograms

Phase: N/A Priority: Normal

NCT ID: NCT01164475 Org: User:

Start: 10/31/10 End: 02/28/13 Due: 02/28/14

AMD3100 (Plerixafor) With G-CSF in Poor Mobilizing Adult Patients Who Previously Failed Hematopoietic Stem Cell (HSC) Collection/Attempts

Phase: N/A Priority: Normal

NCT ID: NCT00396331 Org: User:

Start: 10/31/05 End: 12/31/09 Due: 12/31/10

ZD6474 in Treating Patients With Small Cell Lung Cancer

Phase: N/A Priority: Normal

NCT ID: NCT00066313 Org: User:

Start: 05/31/03 End: 12/31/06 Due: 12/31/07

Vandetanib Risk Minimisation Effectiveness

Phase: N/A Priority: Normal

NCT ID: NCT01757470 Org: User:

Start: 06/30/12 End: 02/28/14 Due: 02/28/15

A Study of the Safety and Efficacy of Synvisc in Patients With Symptomatic Shoulder Osteoarthritis

Phase: N/A Priority: Normal

NCT ID: NCT00131300 Org: User:

Start: 04/30/04 End: 02/28/06 Due: 02/28/07

A Multinational, Randomized, Double-blind, Placebo-controlled Study to Assess the Efficacy, Pharmacodynamics, Pharmacokinetics, and Safety of Venglustat in Late-onset GM2

Phase: N/A Priority: Normal

NCT ID: NCT04221451 Org: User:

Start: 06/29/20 End: 12/26/24 Due: 12/26/25

E3 Breast Cancer Taxotere Combination

Phase: N/A Priority: Normal

NCT ID: NCT00494481 Org: User:

Start: 01/31/06 End: 01/31/09 Due: 01/31/10

Fludara (Oral) Phase II Study for Indolent Lymphoma

Phase: N/A Priority: Normal

NCT ID: NCT00688883 Org: User:

Start: 02/28/03 End: 08/31/04 Due: 08/31/05

A Phase II Study Comparing Low- and High-Dose Alemtuzumab and High-Dose Rebif® in Patients With Early, Active Relapsing-Remitting Multiple Sclerosis

Phase: N/A Priority: Normal

NCT ID: NCT00050778 Org: User:

Start: 12/31/02 End: 01/31/10 Due: 01/31/11

Mobilization of Stem Cells With AMD3100 (Plerixafor) in Multiple Myeloma Patients

Phase: N/A Priority: Normal

NCT ID: NCT00103662 Org: User:

Start: 01/31/05 End: 01/31/08 Due: 01/31/09

Alglucosidase Alfa Pompe Safety Sub-Registry

Phase: N/A Priority: Normal

NCT ID: NCT01710813 Org: User:

Start: 03/20/15 End: 04/20/21 Due: 04/20/22

Study Comparing Thyrogen Versus a Modified Release of Recombinant Human Thyroid Stimulating Hormone

Phase: N/A Priority: Normal

NCT ID: NCT00137891 Org: User:

Start: 06/30/05 End: 08/31/05 Due: 08/31/06

A Study of the Safety and Efficacy of Synvisc and Depo-Medrol in Patients With Osteoarthritis of the Hip

Phase: N/A Priority: Normal

NCT ID: NCT00131326 Org: User:

Start: 11/30/03 End: 04/30/06 Due: 04/30/07

CAPRELSA® REGISTRY: a Belgian Registry to Evaluate the Use of Vandetanib (Caprelsa®) in Current Clinical Practice

Phase: N/A Priority: Normal

NCT ID: NCT02109250 Org: User:

Start: 04/30/14 End: 06/30/15 Due: 06/30/16

Vaccine Therapy in Treating Patients Who Have Stage II, Stage III, or Stage IV Melanoma

Phase: N/A Priority: Normal

NCT ID: NCT00010309 Org: User:

Start: 11/30/00 End: - Due: -

Immune Tolerance Study With Aldurazyme® (Laronidase)

Phase: N/A Priority: Normal

NCT ID: NCT00741338 Org: User:

Start: 09/30/08 End: 09/30/12 Due: 09/30/13

Phase II Study of Clofarabine in Pediatric Acute Lymphoblastic Leukemia (ALL)

Phase: N/A Priority: Normal

NCT ID: NCT00042341 Org: User:

Start: 05/31/02 End: 01/31/06 Due: 01/31/07

Taste Evaluation of Different Liquid Formulations With Eliglustat

Phase: N/A Priority: Normal

NCT ID: NCT02422654 Org: User:

Start: 04/30/15 End: 05/31/15 Due: 05/31/16

A Study of the Safety and Efficacy of rhGAA in Patients With Infantile-onset Pompe Disease

Phase: N/A Priority: Normal

NCT ID: NCT00059280 Org: User:

Start: 04/30/03 End: 09/30/05 Due: 09/30/06

Evaluate Efficacy and Safety in Chinese Patients With Infantile-Onset Pompe Disease With One Year Alglucosidase Alfa Treatment

Phase: N/A Priority: Normal

NCT ID: NCT03687333 Org: User:

Start: 12/04/18 End: 12/30/20 Due: 12/30/21

Title	NCT ID	Organization	User	Status	Start Date	End Date	Reporting Due Date	Last Checked	User Role	Org Created
Plerixafor Plus Granulocyte Colony-stimulating Factor (G-CSF) For Mobilization And Collection Of Peripheral Hematopoietic Stem Cells In Japanese Participants With Multiple Myeloma	NCT02221479	Genzyme, a Sanofi Company	user2@example.com	None	2014-10-31	2015-07-31	2016-07-31	-	-	2025-07-14
Fabry Disease Registry & Pregnancy Sub-registry	NCT00196742	Genzyme, a Sanofi Company	user2@example.com	None	2001-07-31	2034-01-31	2035-01-31	-	-	2025-07-14
LEMTRADA Pregnancy Registry in Multiple Sclerosis	NCT03774914	Genzyme, a Sanofi Company	user2@example.com	None	2015-09-01	2021-11-22	2022-11-22	-	-	2025-07-14
Treatment With AMD3100 (Plerixafor) in MM Patients to Mobilize PBCs For Collection and for Transplantation	NCT00396383	Genzyme, a Sanofi Company	user2@example.com	None	2004-11-30	2007-05-31	2008-05-31	-	-	2025-07-14
A Screening Study Evaluating Disease Status of Gaucher Type I Patients	NCT00795197	Genzyme, a Sanofi Company	user2@example.com	None	2008-12-31	2009-12-31	2010-12-31	-	-	2025-07-14
Evaluation of Approved Weight-Based Dose Compared to Fixed Dose of Plerixafor in Patients With Non-Hodgkin's Lymphoma (NHL) Weighing Less Than 70 Kilograms	NCT01164475	Genzyme, a Sanofi Company	user2@example.com	None	2010-10-31	2013-02-28	2014-02-28	-	-	2025-07-14
AMD3100 (Plerixafor) With G-CSF in Poor Mobilizing Adult Patients Who Previously Failed Hematopoietic Stem Cell (HSC) Collection/Attempts	NCT00396331	Genzyme, a Sanofi Company	user2@example.com	None	2005-10-31	2009-12-31	2010-12-31	-	-	2025-07-14
ZD6474 in Treating Patients With Small Cell Lung Cancer	NCT00066313	Genzyme, a Sanofi Company	user2@example.com	None	2003-05-31	2006-12-31	2007-12-31	-	-	2025-07-14
Vandetanib Risk Minimisation Effectiveness	NCT01757470	Genzyme, a Sanofi Company	user2@example.com	None	2012-06-30	2014-02-28	2015-02-28	-	-	2025-07-14
A Study of the Safety and Efficacy of Synvisc in Patients With Symptomatic Shoulder Osteoarthritis	NCT00131300	Genzyme, a Sanofi Company	user2@example.com	None	2004-04-30	2006-02-28	2007-02-28	-	-	2025-07-14
A Multinational, Randomized, Double-blind, Placebo-controlled Study to Assess the Efficacy, Pharmacodynamics, Pharmacokinetics, and Safety of Venglustat in Late-onset GM2	NCT04221451	Genzyme, a Sanofi Company	user2@example.com	None	2020-06-29	2024-12-26	2025-12-26	-	-	2025-07-14
E3 Breast Cancer Taxotere Combination	NCT00494481	Genzyme, a Sanofi Company	user2@example.com	None	2006-01-31	2009-01-31	2010-01-31	-	-	2025-07-14
Fludara (Oral) Phase II Study for Indolent Lymphoma	NCT00688883	Genzyme, a Sanofi Company	user2@example.com	None	2003-02-28	2004-08-31	2005-08-31	-	-	2025-07-14
A Phase II Study Comparing Low- and High-Dose Alemtuzumab and High-Dose Rebif® in Patients With Early, Active Relapsing-Remitting Multiple Sclerosis	NCT00050778	Genzyme, a Sanofi Company	user2@example.com	None	2002-12-31	2010-01-31	2011-01-31	-	-	2025-07-14
Mobilization of Stem Cells With AMD3100 (Plerixafor) in Multiple Myeloma Patients	NCT00103662	Genzyme, a Sanofi Company	user2@example.com	None	2005-01-31	2008-01-31	2009-01-31	-	-	2025-07-14
Alglucosidase Alfa Pompe Safety Sub-Registry	NCT01710813	Genzyme, a Sanofi Company	user2@example.com	None	2015-03-20	2021-04-20	2022-04-20	-	-	2025-07-14
Study Comparing Thyrogen Versus a Modified Release of Recombinant Human Thyroid Stimulating Hormone	NCT00137891	Genzyme, a Sanofi Company	user2@example.com	None	2005-06-30	2005-08-31	2006-08-31	-	-	2025-07-14
A Study of the Safety and Efficacy of Synvisc and Depo-Medrol in Patients With Osteoarthritis of the Hip	NCT00131326	Genzyme, a Sanofi Company	user2@example.com	None	2003-11-30	2006-04-30	2007-04-30	-	-	2025-07-14
CAPRELSA® REGISTRY: a Belgian Registry to Evaluate the Use of Vandetanib (Caprelsa®) in Current Clinical Practice	NCT02109250	Genzyme, a Sanofi Company	user2@example.com	None	2014-04-30	2015-06-30	2016-06-30	-	-	2025-07-14
Vaccine Therapy in Treating Patients Who Have Stage II, Stage III, or Stage IV Melanoma	NCT00010309	Genzyme, a Sanofi Company	user2@example.com	None	2000-11-30	-	-	-	-	2025-07-14
Immune Tolerance Study With Aldurazyme® (Laronidase)	NCT00741338	Genzyme, a Sanofi Company	user2@example.com	None	2008-09-30	2012-09-30	2013-09-30	-	-	2025-07-14
Phase II Study of Clofarabine in Pediatric Acute Lymphoblastic Leukemia (ALL)	NCT00042341	Genzyme, a Sanofi Company	user2@example.com	None	2002-05-31	2006-01-31	2007-01-31	-	-	2025-07-14
Taste Evaluation of Different Liquid Formulations With Eliglustat	NCT02422654	Genzyme, a Sanofi Company	user2@example.com	None	2015-04-30	2015-05-31	2016-05-31	-	-	2025-07-14
A Study of the Safety and Efficacy of rhGAA in Patients With Infantile-onset Pompe Disease	NCT00059280	Genzyme, a Sanofi Company	user2@example.com	None	2003-04-30	2005-09-30	2006-09-30	-	-	2025-07-14
Evaluate Efficacy and Safety in Chinese Patients With Infantile-Onset Pompe Disease With One Year Alglucosidase Alfa Treatment	NCT03687333	Genzyme, a Sanofi Company	user2@example.com	None	2018-12-04	2020-12-30	2021-12-30	-	-	2025-07-14

Compliance Rate

My Organizations' Clinical Trials

Appearance